Guardant Health, Inc. $GH Stake Lessened by MSH Capital Advisors LLC

Posted by George Bondi on May 27th, 2026

MSH Capital Advisors LLC lessened its holdings in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 46.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,937 shares of the company’s stock after selling 5,916 shares during the period. MSH Capital Advisors LLC’s holdings in Guardant Health were worth $709,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Knights of Columbus Asset Advisors LLC acquired a new stake in Guardant Health during the 3rd quarter worth about $1,554,000. Erste Asset Management GmbH grew its stake in Guardant Health by 10.4% during the 3rd quarter. Erste Asset Management GmbH now owns 705,217 shares of the company’s stock valued at $43,716,000 after acquiring an additional 66,617 shares in the last quarter. Segall Bryant & Hamill LLC increased its holdings in shares of Guardant Health by 57.8% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 305,147 shares of the company’s stock valued at $19,066,000 after purchasing an additional 111,822 shares during the period. TD Asset Management Inc increased its holdings in shares of Guardant Health by 16.1% in the 3rd quarter. TD Asset Management Inc now owns 188,810 shares of the company’s stock valued at $11,797,000 after purchasing an additional 26,210 shares during the period. Finally, GSA Capital Partners LLP lifted its position in shares of Guardant Health by 155.5% in the third quarter. GSA Capital Partners LLP now owns 21,982 shares of the company’s stock worth $1,373,000 after purchasing an additional 13,378 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Insider Transactions at Guardant Health

In related news, insider Terilyn J. Monroe sold 3,832 shares of the stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $92.68, for a total value of $355,149.76. Following the transaction, the insider owned 20,990 shares in the company, valued at approximately $1,945,353.20. This represents a 15.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John G. Saia sold 20,000 shares of the stock in a transaction that occurred on Wednesday, May 20th. The stock was sold at an average price of $106.51, for a total value of $2,130,200.00. Following the completion of the transaction, the insider owned 45,950 shares in the company, valued at $4,894,134.50. This represents a 30.33% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 321,244 shares of company stock valued at $34,775,166 in the last ninety days. 5.60% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on GH shares. JPMorgan Chase & Co. boosted their price objective on shares of Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Barclays increased their target price on shares of Guardant Health from $115.00 to $120.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. Citigroup boosted their price target on shares of Guardant Health from $135.00 to $150.00 and gave the company a “buy” rating in a report on Friday, February 20th. Piper Sandler set a $127.00 price target on shares of Guardant Health in a research note on Thursday, May 21st. Finally, UBS Group reiterated a “buy” rating and set a $175.00 price objective on shares of Guardant Health in a report on Friday, January 30th. Nineteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $129.53.

Check Out Our Latest Stock Analysis on Guardant Health

Guardant Health Stock Performance

NASDAQ:GH opened at $119.85 on Wednesday. The stock’s 50 day moving average price is $92.53 and its 200 day moving average price is $99.26. Guardant Health, Inc. has a 52 week low of $37.73 and a 52 week high of $121.01. The company has a market capitalization of $15.89 billion, a P/E ratio of -35.35 and a beta of 1.48.

About Guardant Health

(Free Report)

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.